Home › Funds › Dundas Partners LLP › ABT
Dundas Partners LLP position in ABT
ABBOTT LABORATORIES · Health Care
Dundas Partners LLP reported holding 398,265 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$39.4M, representing 3.12% of its reported portfolio and ranking #14 among its reported holdings. Dundas Partners LLP has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Dundas Partners LLP's ABT position evolved
Dundas Partners LLP first disclosed a stake in ABT in Q3 2023 at 323,330 shares (US$31.3M). The position peaked in Q3 2025 at 442,954 shares, worth US$59.3M. Across 13 filings, Dundas Partners LLP increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 398,265 shares valued at US$39.4M — a reduction of -25,668 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 323.33K | $31.32M | New |
| Q4 2023 | 323.33K | $35.59M | Hold |
| Q1 2024 | 323.33K | $36.75M | Hold |
| Q2 2024 | 330.23K | $34.31M | Add |
| Q3 2024 | 345.05K | $39.34M | Add |
| Q4 2024 | 345.05K | $39.03M | Hold |
| Q1 2025 | 345.05K | $45.77M | Hold |
| Q2 2025 | 371.71K | $50.56M | Add |
| Q3 2025 | 442.95K | $59.33M | Add |
| Q4 2025 | 428.31K | $53.66M | Reduce |
| Q1 2026 | 423.93K | $43.53M | Reduce |
| Q2 2026 | 423.93K | $38.47M | Hold |
| Q3 2026 | 398.26K | $39.36M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 44.98M sh · $4.45B · Q3 2026
- Capital International Investors 35.46M sh · $3.51B · Q3 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Franklin Resources 20.44M sh · $2.36B · Q3 2026
- Deutsche Bank AG 17.69M sh · $1.75B · Q3 2026
- MFS Investment Management 14.93M sh · $1.48B · Q3 2026
More on Dundas Partners LLP
FAQ
How long has Dundas Partners LLP held ABT?
Dundas Partners LLP has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Dundas Partners LLP's current position in ABT?
As of Q3 2026, Dundas Partners LLP holds 398.26K shares of ABT (ABBOTT LABORATORIES), valued at $39.36M, representing 3.12% of its reported portfolio and ranking #14.
Has Dundas Partners LLP been buying or selling ABT?
In the latest 13F filing (Q3 2026), Dundas Partners LLP reduced its position in ABT. The position peaked in Q3 2025 at 442.95K shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.